Neurofibromatose Typ 2: Behandlung
Über den Vortrag
Der Vortrag „Neurofibromatose Typ 2: Behandlung“ von Roy Strowd, MD ist Bestandteil des Kurses „ZNS-Tumore“.
Quiz zum Vortrag
What is the mechanism of action of bevacizumab?
- Anti-VEGF monoclonal antibody
- Anti-GPIIb/llla monoclonal antibody
- Anti-ERBB2 monoclonal antibody
- Anti-CD20 monoclonal antibody
- Anti-CD3 monoclonal antibody
Radiation treatment is avoided in neurofibromatosis type 2 because it ...
- ... increases the risk of developing secondary tumors.
- ... does not cause shrinkage of the tumor.
- ... prevents further treatment by surgery.
- ... interferes with eventual chemotherapy.
- ... unnecessarily damages healthy brain tissue.
Diese Kurse könnten Sie interessieren
Dozent des Vortrages Neurofibromatose Typ 2: Behandlung
Roy Strowd, MD
Dr. Roy Strowd is the Assistant Dean of Undergraduate Medical Education at the Wake Forest Baptist Medical Center, in North Carolina, USA.
He obtained his MD from Wake Forest School of Medicine in 2009, and his MEd from Johns Hopkins University in 2021. Currently, he co-directs the Neurofibromatosis and Tuberous Sclerosis Clinics at Wake Forest Baptist Medical Center, and is a researcher for the Adult Brain Tumor Consortium (ABTC) and Alliance for Clinical Trials in Neuro-Oncology.
Due to his achievements, he earned the M. Brownell Anderson Award from the Association of American Medical Colleges.
Within Lecturio, Dr. Strowd teaches courses on Clinical Neurology.
Kundenrezensionen
5,0 von 5 Sternen
| 5 Sterne |
|
5 |
| 4 Sterne |
|
0 |
| 3 Sterne |
|
0 |
| 2 Sterne |
|
0 |
| 1 Stern |
|
0 |
